Literature DB >> 18755494

Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion.

Shuji Momose1, Jun-ichi Tamaru, Hirohisa Kishi, Ittaku Mikata, Masaya Mori, Yasuo Toyozumi, Shinji Itoyama.   

Abstract

Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma is a rare subtype of diffuse large B-cell lymphoma (DLBCL). Although a few cases of ALK-positive large B-cell lymphoma harbor nucleophosmin-ALK chromosomal translocation similar to ALK-positive anaplastic large cell lymphoma, most reported cases are characterized by t(2;17)(p23;q23) involving the clathrin gene. Here, we report 2 cases of ALK-positive DLBCL. The 2 cases presented similar morphologic features and immunohistochemical characteristics, that is, positivity for ALK, IgA, CD138, and MUM1; weak positivity for CD30 and CD79a; and negativity for CD20. The clathrin-ALK transcript was identified by reverse transcription-polymerase chain reaction, and the sequence was determined by direct sequencing. Recently, the essential role of STAT3 activation as well as STAT 5 activation in nucleophosmin-ALK fusion protein-mediated lymphomagenesis was reported. However, differential effects of ALK-fusion variant proteins on proliferation, transformation, and invasion properties were reported. Thus, we evaluated the phosphorylation status of STAT 3 and STAT 5, and found highly hyperphosphorylated STAT 3 on tyrosine 705 but not STAT 5 in our 2 cases of ALK-positive DLBCL with clathrin-ALK fusion. Furthermore, STAT 5A expression was not detected in either of the ALK-positive DLBCL cases, although 11 of the 36 ALK-negative DLBCL cases revealed STAT 5A expression. Expression of the antiapoptotic proteins survivin and BCL-X(L), which were believed to be the targets of STAT 3, was investigated. However, there were no significant associations between expression of survivin or BCL-X(L) and ALK positivity among the diffuse large B-cell lymphomas. In summary, similar signaling transduction mechanism involving STAT proteins seems to underlie DLBCL harboring the clathrin-ALK or nucleophosmin-ALK fusion gene.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18755494     DOI: 10.1016/j.humpath.2008.06.009

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  15 in total

1.  ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions.

Authors:  Katrien Van Roosbroeck; Jan Cools; Daan Dierickx; José Thomas; Peter Vandenberghe; Michel Stul; Jan Delabie; Chris De Wolf-Peeters; Peter Marynen; Iwona Wlodarska
Journal:  Haematologica       Date:  2010-03       Impact factor: 9.941

2.  Clathrin heavy chain gene fusions expressed in human cancers: analysis of cellular functions.

Authors:  Maria K E Blixt; Stephen J Royle
Journal:  Traffic       Date:  2011-03-24       Impact factor: 6.215

3.  NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma.

Authors:  Seong-Su Han; Hwakyung Yun; Dong-Ju Son; Van S Tompkins; Liangping Peng; Seung-Tae Chung; Joong-Su Kim; Eun-Sung Park; Siegfried Janz
Journal:  Mol Cancer       Date:  2010-04-30       Impact factor: 27.401

4.  Anaplastic lymphoma kinase-positive large B-cell lymphoma: a distinct clinicopathological entity.

Authors:  Shiyong Li
Journal:  Int J Clin Exp Pathol       Date:  2009-03-13

Review 5.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

6.  Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.

Authors:  Leandro Cerchietti; Christine Damm-Welk; Inga Vater; Wolfram Klapper; Lana Harder; Christiane Pott; Shao Ning Yang; Alfred Reiter; Reiner Siebert; Ari Melnick; Willi Woessmann
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

7.  Anaplastic lymphoma kinase-positive large B-cell lymphoma: an underrecognized aggressive lymphoma.

Authors:  Elizabeth A Morgan; Alessandra F Nascimento
Journal:  Adv Hematol       Date:  2012-02-26

8.  ALK Signaling and Target Therapy in Anaplastic Large Cell Lymphoma.

Authors:  Fabrizio Tabbó; Antonella Barreca; Roberto Piva; Giorgio Inghirami
Journal:  Front Oncol       Date:  2012-05-11       Impact factor: 6.244

Review 9.  Anaplastic lymphoma kinase: signalling in development and disease.

Authors:  Ruth H Palmer; Emma Vernersson; Caroline Grabbe; Bengt Hallberg
Journal:  Biochem J       Date:  2009-05-27       Impact factor: 3.857

10.  NPM-ALK: The Prototypic Member of a Family of Oncogenic Fusion Tyrosine Kinases.

Authors:  Joel D Pearson; Jason K H Lee; Julinor T C Bacani; Raymond Lai; Robert J Ingham
Journal:  J Signal Transduct       Date:  2012-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.